NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017
| Autor: | Stefan K. Barta, Michael Boyer, Mark R. Litzow, Patrick A. Brown, Peter F. Coccia, Eunice S. Wang, Bijal D. Shah, Anjali S. Advani, Jeffrey E. Rubnitz, Lloyd E. Damon, Ndiya Ogba, Kristina M. Gregory, Ayman Saad, Rebecca B. Klisovic, Patricia Aoun, Steven Coutre, Ryan J. Mattison, John P. Greer, Arthur Liu, Gary M. Kupfer, Amir T. Fathi, Ryan Cassaday, Matthew J. Wieduwilt, Patrick W. Burke, Hagop M. Kantarjian, Jae H. Park, Geoffrey L. Uy, Daniel J. DeAngelo, Olga Frankfurt, Teresa J. Bryan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Hematopoietic cell business.industry Standard treatment Lymphoblastic Leukemia Newly diagnosed Intensive chemotherapy Guideline Precursor Cell Lymphoblastic Leukemia-Lymphoma History 21st Century Precursor Cell Lymphoblastic Leukemia Lymphoma Transplantation 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology 030220 oncology & carcinogenesis medicine Humans Intensive care medicine business |
| Zdroj: | Journal of the National Comprehensive Cancer Network : JNCCN. 15(9) |
| ISSN: | 1540-1413 |
| Popis: | The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, the management of relapsed or refractory (R/R) ALL remains challenging and prognosis is poor. The NCCN Guidelines for ALL provide recommendations on standard treatment approaches based on current evidence. These NCCN Guidelines Insights summarize treatment recommendations for R/R ALL and highlight important updates, and provide a summary of the panel's discussion and underlying data supporting the most recent recommendations for R/R ALL management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|